Ā | Screened after invitation1 | Routine opportunistic testing2 | Ā | Sporadic opportunistic testing3 | Ā | |||||
---|---|---|---|---|---|---|---|---|---|---|
nā=ā514,833 (71.2Ā %) | nā=ā149,778 (20.7Ā %) | Ā | nā=ā58,590 (8.1Ā %) | |||||||
Ā | n | % | n | % | PPD % (95Ā % CI)4 | PPR (95Ā % CI)5 | n | % | PPD % (95Ā % CI)6 | PPR (95Ā % CI)7 |
Cytological diagnosis | ||||||||||
Normal cells | 478,855 | (93.0) | 136,797 | (91.3) | ā1.7 (ā1.87; ā1.52) | 0.98 (0.98;0.98) | 53,866 | (91.9) | ā1.1 (ā1.34; ā0.86) | 0.99 (0.99;0.99) |
ASCUS | 10,868 | (2.1) | 3,674 | (2.5) | 0.4 (ā0.17; 0.95) | 1.16 (1.12;1.21) | 1,361 | (2.3) | 0.2 (ā0.64;1.04) | 1.10 (1.04;1.16) |
ASC-H | 2,175 | (0.4) | 846 | (0.6) | 0.2 (ā0.38; 0.78) | 1.34 (1.24;1.45) | 250 | (0.4) | 0.0 (ā0.83; 0.83) | 1.01 (0.89;1.15) |
AGC | 634 | (0.1) | 236 | (0.2) | 0.1 (ā0.52; 0.72) | 1.28 (1.10;1.49) | 99 | (0.2) | 0.1 (ā0.81; 1.01) | 1.37 (1.11;1.70) |
LSIL | 7,857 | (1.5) | 2,760 | (1.8) | 0.3 (ā0.26; 0.86) | 1.21 (1.16;1.26) | 945 | (1.6) | 0.1 (ā0.74; 0.94) | 1.06 (0.99;1.13) |
HSIL | 4,791 | (0.9) | 2,228 | (1.5) | 0.6 (0.03; 1.17) | 1.60 (1.52;1.68) | 408 | (0.7) | ā0.2 (ā1.05; 0.65) | 0.75 (0.68;0.83) |
Carcinoma in situā+āAIS | 106 | (0.02) | 45 | (0.03) | 0.01 (ā0.56; 0.58) | 1.46 (1.00;2.07) | 14 | (0.02) | 0.0 (ā0.79; 0.79) | 1.16 (0.66;2.03) |
Carcinoma8 | 42 | (0.01) | 42 | (0.03) | 0.02 (ā0.58; 0.62) | 3.44 (2.24;5.27) | 2 | (0.0) | ā0.01 (ā0.31; 0.29) | 0.42 (0.10;1.72) |
Inadequate cervical cytology9 | 9,109 | (1.8) | 2,988 | (2.0) | 0.2 (ā0.37; 0.77) | 1.13 (1.08;1.17) | 1,538 | (2.6) | 0.8 (ā0.04; 1.64) | 1.48 (1.40;1.56) |
Others10 | 29 | (0.01) | 8 | (0.01) | 0.0 (ā0.78; 0.78) | 0.95 (0.43;2.07) | 1 | (0.0) | NA | NA |